Liquidia (LQDA) Chief Business Officer Jason Sells $208K of Stock

Adair Jason, the Chief Business Officer of Liquidia Corporation (LQDA), sold 7,301 shares on October 12, 2026, for about $207,932.48. This transaction was part of a planned sale.

Inside Adair Jason's Trade

Jason's sale of 7,301 shares comes at a price of $28.48 each, which aligns with the recent trading activity of the company. Liquidia Corporation focuses on developing treatments for rare cardiopulmonary diseases, including its lead product YUTREPIA for pulmonary arterial hypertension.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. holds 10,788,586 shares of Liquidia, valued at approximately $370.6 million after increasing its stake by 529,932 shares, a 96.5% rise. Farallon Capital Management LLC has reduced its holdings by 290,837 shares, leaving it with 8,365,038 shares worth about $287.3 million, a 3.4% decrease. Caligan Partners, LP remains steady with 8,118,892 shares, while Findell Capital Management LLC and Vanguard Capital Management LLC have 3,502,112 shares and 3,139,183 shares, respectively.

Liquidia Corporation Stock Down 2.9%

Liquidia's stock recently traded around $33.77 as of October 16, 2026. This price is significantly below its 50-day moving average of $61.62 and its 200-day average of $53.93, indicating a downward trend. The stock is also trading 63.9% below its 52-week high of $93.61, but 53.9% above its 52-week low of $21.94.

Recent Earnings

Liquidia Corporation reported trailing twelve-month revenue of $450.9 million, with an impressive year-over-year revenue growth of 1,842.7%. The company's earnings per share (EPS) stands at $1.39, with a net margin of 30.7%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Jason's sale, other insiders also sold shares. Russell Schundler, the General Counsel, sold 13,692 shares for about $389,948. Chief Medical Officer Saggar Rajeev sold 9,218 shares valued at approximately $262,528.64, while Chief Commercial Officer Scott Moomaw sold 8,863 shares for around $252,418.24. All these transactions were planned sales.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia to an "Outperform" rating with a new price target of $53, down from $106. BTIG also downgraded the stock to "Neutral". Needham maintained a "Buy" rating with a target of $72, while Wells Fargo downgraded it to "Equal-Weight" with a target of $30. HC Wainwright & Co. maintained a "Buy" rating with a target of $58.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company that develops and commercializes products for rare cardiopulmonary diseases. Its lead product, YUTREPIA, aims to treat pulmonary arterial hypertension and related conditions. The recent insider trading activity reflects ongoing adjustments within the company's leadership.

Bottom Line

Investors should watch for Liquidia's next earnings date on November 3, 2026, as well as any further insider trading activity. This recent sale by Adair Jason and other executives may indicate strategic moves within the company as it navigates its market position.